'On track to become a blockbuster': FDA approves injectable form of argenx's autoimmune drug

Ryan Cross

Senior Science Correspondent

The Dutch biotech company argenx won FDA approval on Tuesday for an easier-to-administer version of its autoimmune disease drug efgartigimod. The new version, marketed at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'On track to become a blockbuster': FDA approves injectable form of argenx's autoimmune drug

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

'On track to be­come a block­buster': FDA ap­proves in­jectable form of ar­genx's au­toim­mune drug

Ryan Cross

Senior Science Correspondent

Sign up to read this article for free.

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Boston Phar­ma­ceu­ti­cals hits Phase 2 goals as it tries to keep up with MASH com­peti­tors

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

'On track to become a blockbuster': FDA approves injectable form of argenx's autoimmune drug

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

Trump picks vaccine skeptic Kennedy to lead HHS, in what would be an upheaval of US health policy

Eisai terminates Phase 3 trial of Dravet drug, citing recruitment challenges

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Boston Pharmaceuticals hits Phase 2 goals as it tries to keep up with MASH competitors

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?